Mobocertinib NDA receives FDA Priority Review as treatment for EGFR Exon20 insertion+ metastatic NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mobocertinib (TAK-788) has received FDA Priority Review for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. 

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


Spanning part of September and October, it is a time to celebrate and recognize Hispanics or Latinos or Latinx persons* for their contributions. This nationwide observation begins on Sept. 15 when several countries in Latin America celebrate independence—Costa Rica, El Salvador, Guatemala, Honduras, and Nicaragua. Mexico celebrates independence on Sept. 16 and Chile on Sept. 18. Towards the end of Hispanic Heritage Month, Oct. 12 is also recognized as Día de la Raza.1 Persons of Hispanic ancestry have walked the Americas since 1492.